VOOPOO
2.12.2021 10:37:10 CET | Business Wire | Press release
In November, VOOPOO announced the overseas launch of the DRAG S/X PnP-X KIT. The product carries out comprehensive technical upgrading on the basis of DRAG S/X, endows the core concept of "Chivalry" in product design, and pays tribute to the glory and virtue of knights.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005381/en/
Originated from the spirit of martial arts of German in the Middle Ages, the spirit of chivalry was then embodied in soldiers of the European battlefield in the 11th century, and guards of emperors and warriors of Christ. Nowadays, chivalry is culturally continued and nobly expressed as gentleman demeanor. Despite passage of time, the only constant is the faith that knight loyally holds and eight virtues of knights flowing in their blood. After learning about this legendary medieval history and digging out the core of chivalry, VOOPOO design and R&D personnel were deeply touched. The four core propositions of " Honor", " Valor", "Justice" and "Spirituality" were included in DRAG S/X PnP-X KIT product for consumers to discover. Every vaping is a fusion of VOOPOO and the connotation of the knight, and every piece of cloud is a spiritual portrait of the knight who rushes to the battlefield heroically.
DRAG S/X PnP-X KIT selects five new knight colors, each of which implies a rich design language. Shield Gold--Knight Templar for Defending Justice. Knight Red--Masked Knight for Pursuit Fairness. Knight Chestnut--Dragon Knight for Defending Glory .Eagle Black--Black Knight for Brave and Fearless. Knight Gray--Paladin for Spirituality.
PnP-X Pod displays knight’s spirituality. The metal materials and knob-filling on the top are upgraded, and the 510 drip tip can be replaced at any time. It is anti-leakage, more convenient, and more flexible. Radiating knight spirituality, PnP-X Pod will give you an enjoyable experience in vaping.
The knight series products bring an "Infinite Airflow System" that supports the adjustment of any airway. More than that, knight symbolizes of bravery and heroism. DRAG S/X PnP-X KIT embodies the knight’s valor spirit. It is equipped with a powerful GENE.TT chip, and adjustable power ranging from 5-60/80w. The product can be started in 0.001 second. The hardware is powerful enough that every knight can charge into the battle, with no worries.
The mission of the knight is to guard the country and territory, glory, and faith, and the beloved princess in their hearts. DRAG S/X PnP-X KIT fitted with 2500 mAh built-in battery and 18650 external battery respectively. The Type-C 5V/2A fast charging interface gives every knight full blood for them to resurrect in an instant. To guard the DRAG S/X PnP-X KIT is to guard the spirit of the knight, the cultural connotation of which has been inherited and innovated for thousands of years.
DRAG S/X PnP-X KIT has been upgraded based on DARG S&DARG X. The biggest highlight is the comprehensive upgrade of the atomizer. For one thing, the PnP X Pod has upgraded the metal decorative ring with knight-style texture. For another, the knob-filling on the top, which is more convenient. Anti-leakage design is more compact, and the 510 drip tip can be replaced at any time. In short, the upgrade of DRAG S/X PnP-X KIT is comprehensive, and is worthy of buying. At the same time, a vaper who likes the appearance of knights can't miss this flagship product with "chivalry spirit." Let us pay tribute to the honor of knights together!
Positioning of DRAG S/X PnP-X KIT and DARG S/X PRO is different. DARG S/X PRO is a top-fitting product for professional vapers who want to experience higher power and bigger cloud.
Founded in 2017, VOOPOO has rapidly grown within a short period of time and is now selling worldwide. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operations. It has four flagship product series: DRAG, VINCI, ARGUS and V Series. VOOPOO has more than 3000 employees worldwide and its business covers more than 70 countries and regions in North America, Europe and Asia.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
For more information, please visit https://www.voopoo.com/ , and follow our IG , Facebook and TikTok pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005381/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom